|
**Overview**: Flow Cytometry CD19 Panel**Introduction**: The Flow Cytometry CD19 Panel is a diagnostic tool designed to assess B-cell population using whole blood samples. In India, B-cell disorders (CLL, B-ALL, lymphomas) affect thousands annually, with CD19 as a key pan-B-cell marker for enumeration and characterization in immunophenotyping. High morbidity from under-testing in rural/low-SES patients with lymphocytosis or lymphadenopathy, limited flow cytometry labs, delayed diagnosis leading to progression or inappropriate therapy. Per hematology/immunology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs flow cytometry for CD19+ cell count, total lymphocytes, and B-cell profile over 1-2 days with high accuracy, valuable for leukemia/lymphoma diagnosis and monitoring. This diagnostic falls under immune profiling and targets patients with suspected B-cell malignancy or immunodeficiency, addressing accurate detection to guide targeted therapy (rituximab) or transplant. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise immunophenotyping and improving outcomes. Its whole blood-based approach ensures reliable B-cell analysis.**Other Names**: Flow CD19 Pnl.**FDA Status**: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.**Historical Milestone**: CD19 flow standard; in India, used in leukemia protocols.**Purpose**: The test assesses 3 parameters including CD19+ cell count to guide B-cell population evaluation, detect abnormalities, inform management.**Test Parameters**: 1. CD19+ Cell Count, 2. Total Lymphocytes, 3. B-Cell Profile.**Pretest Condition**: No fasting required; patients should have suspected B-cell disorder.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow).**Medical History**: Patients should provide details on lymphocytosis, lymphadenopathy, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed B-cell disorder including progression, benefits of profiling, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low lymphocyte count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal CD19+ population indicates B-cell disorder, necessitating specialist input. Normal may require follow-up.**Specialist Consultation**: Hematologists/immunologists should be consulted for management.**Additional Supporting Tests**: Full immunophenotyping, bone marrow biopsy for confirmation.**Test Limitations**: Requires viable cells; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Flow Studies India 2023. |
